{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T15:29:02Z","timestamp":1751297342744,"version":"3.41.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>Long follow-up time is needed for overall survival (OS) data to mature for early-stage melanoma. This retrospective study aimed to describe the relationships between OS and two intermediate endpoints \u2013 real-world recurrence-free survival (rwRFS) and real-world distant metastasis-free survival (rwDMFS) \u2013 for patients with stage IIB or IIC melanoma that was completely resected from 1 January 2008 to 31 December 2017, with follow-up to 31 December 2020. We used three different approaches to describe the relationships: estimates of correlation using Kendall \u03c4 rank correlation; comparisons of all-cause survival with\/without recurrence or distant metastasis using adjusted Cox proportional hazard models; and landmark analyses of all-cause survival stratified by recurrence status at 1\u20135 years. During a 39-month median follow-up from surgical resection, 223\/567 patients (39%) experienced recurrence, among whom 171\/567 patients (30%) developed distant metastasis. Median OS from surgical resection was 117.6 months [95% confidence interval (CI), 104.7-not reached], median rwRFS was 49.8 months (95% CI, 39.6\u201361.0), and median rwDMFS was 70.9 months (95% CI, 58.4\u201389.1). We observed strong correlations between rwRFS and OS, and between rwDMFS and OS (Kendall \u03c4 of 0.73 and 0.82, respectively). Risk of death was significantly greater after recurrence (all-cause survival adjusted hazard ratio [HR], 7.48; 95% CI, 4.55\u201312.29) or distant metastasis (adjusted HR, 11.00; 95% CI, 6.92\u201317.49). Risk of death remained significantly elevated with recurrence or distant metastasis by landmark years 1, 3, and 5 after surgical resection. These findings support the use of recurrence\/rwRFS and distant metastasis\/rwDMFS as surrogate endpoints for OS after complete resection of stage IIB or IIC melanoma.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000962","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T16:31:00Z","timestamp":1717086660000},"page":"326-334","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma"],"prefix":"10.1097","volume":"34","author":[{"given":"Wolfram","family":"Samlowski","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada"},{"name":"University of Nevada School of Medicine, Reno"},{"name":"University of Nevada Las Vegas, Las Vegas, Nevada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Silver","sequence":"additional","affiliation":[{"name":"Real World Research, Ontada, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andriana","family":"Hohlbauch","sequence":"additional","affiliation":[{"name":"Real World Research, Ontada, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center for Observational & Real World Evidence (CORE), Merck & Co., Inc., Rahway, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuho","family":"Fukunaga-Kalabis","sequence":"additional","affiliation":[{"name":"Center for Observational & Real World Evidence (CORE), Merck & Co., Inc., Rahway, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Krepler","sequence":"additional","affiliation":[{"name":"Center for Observational & Real World Evidence (CORE), Merck & Co., Inc., Rahway, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfei","family":"Wang","sequence":"additional","affiliation":[{"name":"Real World Research, Ontada, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ila","family":"Sruti","sequence":"additional","affiliation":[{"name":"Real World Research, Ontada, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Center for Observational & Real World Evidence (CORE), Merck & Co., Inc., Rahway, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"R1-20250528","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/cncr.32585","article-title":"Considering adjuvant therapy for stage II melanoma.","volume":"126","author":"Poklepovic","year":"2020","journal-title":"Cancer"},{"key":"R2-20250528","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.surg.2015.12.002","article-title":"Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.","volume":"159","author":"Egger","year":"2016","journal-title":"Surgery"},{"key":"R3-20250528","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R4-20250528","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s13555-020-00404-9","article-title":"Real-world recurrence rates and economic burden in patients with resected early-stage melanoma.","volume":"10","author":"Jang","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R5-20250528","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s13555-020-00422-7","article-title":"Correction to: real-world recurrence rates and economic burden in patients with resected early-stage melanoma.","volume":"10","author":"Jang","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R6-20250528","doi-asserted-by":"crossref","first-page":"MMT33","DOI":"10.2217\/mmt-2019-0015","article-title":"Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review.","volume":"6","author":"Mohr","year":"2019","journal-title":"Melanoma Manag"},{"key":"R7-20250528","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1200\/EDBK_239283","article-title":"Approaches to high-risk resected stage II and III melanoma.","volume":"39","author":"Yushak","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R8-20250528","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(22)00559-9","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.","volume":"23","author":"Long","year":"2022","journal-title":"Lancet Oncol"},{"key":"R9-20250528","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"R12-20250528","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat Med"},{"key":"R13-20250528","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejca.2021.08.028","article-title":"Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.","volume":"158","author":"Weber","year":"2021","journal-title":"Eur J Cancer"},{"key":"R14-20250528","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.001","article-title":"Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.","volume":"119","author":"Eggermont","year":"2019","journal-title":"Eur J Cancer"},{"key":"R15-20250528","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma.","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evidence"},{"key":"R16-20250528","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/jnci\/djx133","article-title":"Relapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy.","volume":"110","author":"Suciu","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"R17-20250528","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2020.07.011","article-title":"Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors.","volume":"137","author":"Coart","year":"2020","journal-title":"Eur J Cancer"},{"key":"R18-20250528","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.2217\/fon-2022-0508","article-title":"Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics.","volume":"18","author":"Samlowski","year":"2022","journal-title":"Future Oncol"},{"key":"R22-20250528","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1162\/coli.2006.32.4.471","article-title":"Automatic evaluation of information ordering: Kendall\u2019s tau.","volume":"32","author":"Lapata","year":"2006","journal-title":"Comput Linguist"},{"key":"R23-20250528","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2307\/2346574","article-title":"The interpretation of rank correlations.","volume":"24","author":"Kerridge","year":"1975","journal-title":"Appl Stat"},{"key":"R24-20250528","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0022-3956(98)90046-2","article-title":"Correlating and predicting psychiatric symptom ratings: Spearman\u2019s r versus Kendall\u2019s tau correlation.","volume":"33","author":"Arndt","year":"1999","journal-title":"J Psychiatr Res"},{"key":"R26-20250528","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3390\/cancers14071804","article-title":"Real-world therapy with pembrolizumab: outcomes and surrogate endpoints for predicting survival in advanced melanoma patients in Germany.","volume":"14","author":"Mohr","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R27-20250528","doi-asserted-by":"crossref","first-page":"e3997","DOI":"10.1097\/MD.0000000000003997","article-title":"Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials.","volume":"95","author":"Petrelli","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"R28-20250528","doi-asserted-by":"crossref","first-page":"100340","DOI":"10.1016\/j.esmoop.2021.100340","article-title":"Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial.","volume":"7","author":"Branchoux","year":"2022","journal-title":"ESMO Open"},{"key":"R29-20250528","doi-asserted-by":"crossref","first-page":"100272","DOI":"10.1016\/j.ctarc.2020.100272","article-title":"Exploring the relationship between overall survival (OS), progression free survival (PFS) and objective response rate (ORR) in patients with advanced melanoma.","volume":"26","author":"Sheth","year":"2021","journal-title":"Cancer Treat Res Commun"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:42:26Z","timestamp":1748468546000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000962","relation":{},"ISSN":["0960-8931"],"issn-type":[{"type":"print","value":"0960-8931"}],"subject":[],"published":{"date-parts":[[2024,5,27]]}}}